Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 6;116(9):1439–1449. doi: 10.1093/jnci/djae098

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Efficacy by dose group. A) Overall response. B) Change from baseline in tumor size by dose group. C) ctDNA responses by dose group. 2/1w = 2 weeks on, 1 week off; 120 3/4 =120 mg QD 3 days on, 4 days off; 160 3/4 = 160 mg QD 3 days on, 4 days off; CA-125 = cancer antigen 125; cCR = confirmed CR; cPR = confirmed PR; CR = complete response; ctDNA = circulating tumor DNA; GI = gastrointestinal; mVAF = mean variant allele frequency; NSCLC = non-small cell lung cancer; PR = partial response; PSA = prostate-specific antigen; QD = once daily; uPR = unconfirmed PR.